EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning

Sergio Corridore, Maïté Verreault, Hugo Martin, Thibault Delobel, Cécile Carrère, Ahmed Idbaih, Annabelle Ballesta

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70027 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Sergio Corridore and 6 co-authors. Institution: INSERM Unit 1331, Institut Curie, PSL Research University, CBIO-Center for Computational Biology, Mines Paris, Cancer Systems Pharmacology team, Sain…. Major MEDLINE topics: Temozolomide, Glioblastoma, Machine Learning, Drug Resistance, Neoplasm. Cited 4 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National French Plan Cancer through INSERM, ITMO Cancer INSERM, MIC funding, ARC French Charity.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Glioblastoma (GBM), the most frequent and aggressive brain tumour in adults, is associated with a dismal prognostic despite intensive treatment involving surgery, radiotherapy and temozolomide (TMZ)‐based chemotherapy. The initial or acquired resistance of GBM to TMZ appeals for precision medicine approaches to the design of novel efficient combination pharmacotherapies. Such investigation needs to account for the overexpression of the O6‐methylguanine‐DNA methyl‐transferase (MGMT) repair enzyme which is responsible for TMZ resistance in patients. Experimental Approach A comprehensive approach combining quantitative systems pharmacology (QSP) models and machine learning (ML) was undertaken to design TMZ‐based drug combinations circumventing the initial resistance to the alkylating agent. Key Results A QSP model representing TMZ cellular pharmacokinetics‐pharmacodynamics and dysregulated pathways in GBM was developed and validated using multi‐type time‐ and dose‐resolved datasets, available in control or MGMT‐overexpressing cells. In silico drug screening and subsequent experimental validation identified a strategy to re‐sensitise TMZ‐resistant cells consisting in combining TMZ with inhibitors of the base excision repair and of homologous recombination. Using ML, functional signatures of response to such optimal multi‐agent therapy were derived to assist decision‐making in patients. Conclusion and Implications We successfully demonstrated the relevance of combined QSP and ML to design efficient drug combinations re‐sensitising glioblastoma cells initially resistant to TMZ. The developed framework may further serve to identify personalised therapies and administration schedules by extending it to account for additional patient‐specific altered pathways and whole‐body features.

Subjects

MeSH terms (MEDLINE)

TemozolomideGlioblastomaMachine LearningDrug Resistance, NeoplasmBrain NeoplasmsAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsHumansCell Line, TumorDNA Modification MethylasesDNA Repair EnzymesTumor Suppressor Proteins

Author keywords

glioblastomamachine learningpharmacokinetics–pharmacodynamicsprecision medicinesystems pharmacologytemozolomidetherapeutic optimisation

Substances

TemozolomideAntineoplastic Agents, AlkylatingDNA Modification MethylasesMGMT protein, humanDNA Repair EnzymesTumor Suppressor Proteins

Authors and institutions

  • INSERM Unit 1331, Institut Curie, PSL Research University, CBIO-Center for Computational Biology, Mines Paris, Cancer Systems Pharmacology team, Saint Cloud, France.
  • AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, DMU Neurosciences, Service de Neuro-Oncologie-Institut de Neurologie, Sorbonne Univers…
  • University of Rennes, EHESP, CNRS, Inserm, Arènes - UMR 6051, RSMS - U 1309, Rennes, France.
  • Institut Denis Poisson, Université d'Orléans, CNRS, Orléans, France.

Funding

  • National French Plan Cancer through INSERM
  • ITMO Cancer INSERM, MIC funding
  • ARC French Charity
  • Association pour la Recherche Contre les Tumeurs Cérébrales" (ARTC)
  • PSL University-Institut Curie

Cite

APA

Corridore, S., Verreault, M., Martin, H., Delobel, T., Carrère, C., Idbaih, A., & Ballesta, A. (2025). Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning. British Journal of Pharmacology. https://doi.org/10.1111/bph.70027

Vancouver

Corridore S, Verreault M, Martin H, Delobel T, Carrère C, Idbaih A, et al. Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning. British Journal of Pharmacology. 2025. doi:10.1111/bph.70027

BibTeX
@article{Corridore2025,
  author = {Corridore, Sergio and Verreault, Maïté and Martin, Hugo and Delobel, Thibault and Carrère, Cécile and Idbaih, Ahmed and Ballesta, Annabelle},
  title = {Circumventing glioblastoma resistance to temozolomide through optimal drug combinations designed by systems pharmacology and machine learning},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70027}
}
Start for free →